Use and cardiovascular safety of transdermal and other granisetron preparations in cancer management

Article, Review English OPEN
Mason JW; Moon TE;
(2013)

Jay W Mason,1 Thomas E Moon2 1School of Medicine, University of Utah, Salt Lake City, UT, 2Tarizona eHealth Services, Inc, Emeryville, CA, USA Abstract: 5-HT3 antagonists have been available as oral and intravenous preparations for decades. The availability more recent... View more
  • References (31)
    31 references, page 1 of 4

    1. Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol. 1999;17(9):2971-2994.

    2. Roila F, Hesketh PJ, Herrstedt J. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol. 2006;17(1):20-28.

    3. Ihbe-Heffinger A, Ehlken B, Bernard R, et al. The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization, and costs in German cancer centers. Ann Oncol. 2004; 15(3):526-536.

    4. Stewart DJ, Dahrouge S, Coyle D, Evans WK. Costs of treating and preventing nausea and vomiting in patients receiving chemotherapy. J Clin Oncol. 1999;17(1):344-351.

    5. Sykes AJ, Kiltie AE, Stewart AL. Ondansetron versus a chlorpromazine and dexamethasone combination for the prevention of nausea and vomiting: a prospective, randomized study to assess efficacy, cost effectiveness, and quality of life following single-fraction radiotherapy. Support Care Cancer. 1997;5(6):500-503.

    6. Tina Shih YC, Xu Y, Elting LS. Costs of uncontrolled chemotherapyinduced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy. Cancer. 2007;110(3):678-685.

    7. Vanscoy GJ, Fortner B, Smith R, Weber R, Rihn TL. Preventing chemotherapy-induced nausea and vomiting: the economic implications of choosing antiemetics. Community Oncology. 2005;2(2):127-132.

    8. Hesketh PJ, Sanz-Altamira P, Bushey J, Hesketh AM. Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy. Support Care Cancer. 2012;20(5):1043-1047.

    9. Rubenstein EB. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Clin Adv Hematol Oncol. 2004;2(5):284-289.

    10. Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol. 2006;24(27):4472-4478.

  • Related Organizations (2)
  • Metrics
Share - Bookmark